GlaxoSmithKline Update: Government Orders for Pandemic (H1N1) 2009 Vaccine

GlaxoSmithKline Update: Government Orders for Pandemic (H1N1) 2009 Vaccine

London, 06 October 2009, GSK is committed to supporting governments and health authorities around the world respond to the pandemic (H1N1) 2009 influenza strain.

The company today provided an update on orders received for its pandemic (H1N1) adjuvanted vaccine.

On the 4th August, GSK confirmed that it had contracts in place to supply 291 million doses of the vaccine and had a variety of agreements in place with the US Government to supply pandemic products worth $250 million. 

Since that date, 22 government orders have been agreed to supply a further 149 million doses of the vaccine.  This now brings the total number of doses ordered for GSK's pandemic vaccines to 440 million.  Discussions continue with governments for further supplies.

First supplies of the vaccine will be shipped to governments during the week commencing 5th October. Shipments of the vaccine will be delivered in both the fourth quarter of 2009 and the first half of 2010.

The vaccine deliveries are contingent on a number of factors including government import/export regulations, regulatory approvals, approvals for outsourced packaging and filling as well as testing required by reference laboratories. 

GSK will continue to provide regular updates to governments relating to delivery schedules to support them in planning their vaccination programmes.

Further information on GSK's development of vaccines to protect against pandemic (H1N1) 2009, including explanation of the development process and background information on adjuvants is available on: www.gsk.com/media/pandemic-flu.htm

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.